Skip to main content

Table 1 Demographic details of 16 patients who had intravitreal conbercept for choroidal neovascularization secondary to punctate inner choroidopathy

From: Efficacy and safety of conbercept as a primary treatment for choroidal neovascularization secondary to punctate inner choroidopathy

Patient No.

Gender /Age

Refractive diopter

Location of CNV

Best Corrected Visual Acuity

Central Retinal Thickness (μm)

Angiographic Leakage On FA

No. of Injection

    

Baseline

Month 6

Baseline

Month 6

Baseline

Month 6

 

1

F/45

-9

JF

20/200

20/80

256

186

YES

NO

2

2

F/54

-12

SF

20/80

20/50

303

203

YES

NO

1

3

F/31

-4.5

JF

20/160

20/50

207

196

YES

NO

1

4

F/48

-1

JF

20/40

20/40

176

155

YES

NO

1

5

M/66

-9

JF

20/32

20/50

205

295

YES

YES

3

6

F/39

-11.5

SF

20/100

20/32

305

213

YES

NO

2

7

F/48

-14

JF

20/100

20/63

204

150

YES

NO

1

8

F/60

-7.5

SF

20/333

20/80

310

202

YES

NO

3

9

M/28

-9.5

SF

20/50

20/40

457

275

YES

NO

1

10

F/29

-6.5

JF

20/32

20/32

199

194

YES

NO

1

11

F/53

-13

SF

20/400

20/250

326

303

YES

NO

1

12

F/53

-2

JF

20/50

20/40

185

180

YES

NO

1

13

F/76

-9

SF

20/333

20/160

484

301

YES

NO

1

14

M/65

-2

SF

20/50

20/40

428

165

YES

NO

3

15

F/45

0

JF

20/160

20/40

416

75

YES

NO

1

16

F/35

-5

SF

20/125

20/40

258

212

YES

NO

1

  1. CNV choroidal neovascularization F female; M male; SF subfoveal; JF juxtafoveal